LOGIN  |  REGISTER
Astria Therapeutics

Phreesia Sets Release Date for Fiscal Fourth Quarter 2023 Results

February 02, 2023 | Last Trade: US$23.69 0.28 1.20

WILMINGTON, Del. / Feb 02, 2023 / Business Wire / Phreesia, Inc. (NYSE: PHR) (“Phreesia”) today announced that it will release its fiscal fourth quarter 2023 financial results after the close of market trading on Wednesday, March 22, 2023. Phreesia will issue a press release announcing its quarterly results and the company’s quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal fourth quarter results starting at 5 PM Eastern Time on the same day.

To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or visit the “Events & Presentations” section of ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

ABOUT PHREESIA

Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, convenient experience, while enabling our clients to enhance clinical care and drive efficiency. For more information, visit Phreesia.com.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page